Research-Oriented Review of ANP (1-11), rat Mechanisms, Clin

Research-Oriented Review of ANP (1-11), rat: Mechanisms, Clinical Applications, and Future Directions

Introduction
Atrial natriuretic peptide (ANP) is a cardiac hormone with well-established roles in cardiovascular homeostasis, natriuresis, and vasodilation. The biologically active fragment, ANP (1-11), represents the N-terminal 11 amino acids of the full-length peptide and has garnered significant interest in preclinical research, particularly in rodent models. ANP (1-11), rat, is a synthetic peptide corresponding to the rat sequence, widely utilized in experimental studies to elucidate the physiological and pathophysiological roles of natriuretic peptides.

Mechanistically, ANP (1-11) binds to natriuretic peptide receptors (NPRs), primarily NPR-A and NPR-C, leading to the activation of guanylyl cyclase and subsequent elevation of intracellular cyclic guanosine monophosphate (cGMP) levels (Potter et al., 2006, Endocrinology). This cascade results in vasodilation, natriuresis, diuresis, and inhibition of the renin-angiotensin-aldosterone system (RAAS). The N-terminal fragment, while less potent than the full-length peptide in some respects, exhibits unique receptor interactions and may serve as a valuable tool for dissecting the diverse functions of natriuretic peptides in vivo and in vitro (Vollmar, 1997, Cardiovasc Res).

[Related: proteasome inhibitor bortezomib] Clinical Value and Applications
ANP (1-11), rat, is primarily a research reagent rather than a direct clinical therapeutic. Its value lies in its utility for modeling and understanding cardiovascular, renal, and metabolic diseases in preclinical settings. The peptide enables researchers to:
- Investigate the physiological roles of natriuretic peptides in blood pressure regulation, fluid balance, and cardiac remodeling.
- Explore the pathogenesis of hypertension, heart failure, and renal dysfunction.
- Assess the pharmacodynamics and pharmacokinetics of natriuretic peptide analogs and receptor modulators.
- Evaluate potential therapeutic strategies targeting the natriuretic peptide system.

In experimental models, ANP (1-11) has been used to delineate the differential effects of N-terminal and C-terminal peptide fragments, providing insights into receptor specificity and downstream signaling pathways. This is particularly relevant for the development of novel peptide-based therapeutics and for understanding the limitations of current natriuretic peptide-based drugs (Koller et al., 1991, Circ Res).

[Related: ap20187 thermo fisher] Key Challenges and Pain Points Addressed
Current treatments for cardiovascular and renal diseases often face challenges such as limited efficacy, adverse effects, and resistance to standard therapies. The natriuretic peptide system represents a promising target, but the complexity of receptor subtypes and peptide fragments complicates drug development. Key challenges addressed by research using ANP (1-11), rat, include:
- **Dissecting Receptor Specificity:** Full-length ANP and its fragments interact differently with NPR-A, NPR-B, and NPR-C. ANP (1-11) allows for selective probing of N-terminal mediated effects, aiding in the identification of receptor-specific actions (Vollmar, 1997).
- **Understanding Metabolic Stability:** The N-terminal fragment is more susceptible to enzymatic degradation than the C-terminal, providing a model for studying peptide stability and metabolism in vivo (Koller et al., 1991).
- **Modeling Disease States:** By administering ANP (1-11) in rodent models, researchers can mimic or modulate disease phenotypes, such as salt-sensitive hypertension or acute kidney injury, facilitating the evaluation of new therapeutic approaches (Kishimoto et al., 1996, Hypertension).
- **Elucidating Non-Canonical Functions:** Emerging evidence suggests that N-terminal fragments may have unique biological activities, including anti-inflammatory and anti-fibrotic effects, distinct from the full-length peptide (Potter et al., 2006).

Literature Review
A growing body of literature supports the utility of ANP (1-11) in basic and translational research:

[Related: chir 99021] 1. **Koller, K.J., Lowe, D.G., Bennett, G.L., Minamino, N., Kangawa, K., Matsuo, H., & Goeddel, D.V. (1991). Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Circ Res, 69(6), 1523-1529.**
This seminal study characterized the receptor specificity of natriuretic peptide fragments, highlighting the differential activation of NPR subtypes by N-terminal and C-terminal peptides.

2. **Vollmar, A.M. (1997). The role of atrial natriuretic peptide in the immune system. Cardiovasc Res, 34(2), 272-280.**
Vollmar reviewed the immunomodulatory effects of ANP and its fragments, emphasizing the unique properties of the N-terminal region in modulating inflammatory responses.

3. **Potter, L.R., Abbey-Hosch, S., & Dickey, D.M. (2006). Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocrinology, 147(6), 2274-2279.**
This comprehensive review detailed the molecular mechanisms of natriuretic peptide signaling, including the role of N-terminal fragments in receptor binding and cGMP production.

4. **Kishimoto, I., Tokudome, T., & Nakao, K. (1996). The cardiovascular and renal actions of natriuretic peptides: implications for therapy. Hypertension, 27(3), 399-406.**
The authors discussed the therapeutic potential of natriuretic peptides in cardiovascular and renal diseases, with specific reference to the functional differences between peptide fragments.

5. **Kuhn, M. (2016). Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol, 111(6), 71.**
Kuhn provided an updated overview of natriuretic peptide biology, including the pharmacological relevance of N-terminal fragments in experimental models.

6. **Pandey, K.N. (2011). Guanylyl cyclase/atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation. Can J Physiol Pharmacol, 89(8), 557-573.**
This article explored the pathophysiological roles of NPR-A and its ligands, underscoring the importance of peptide fragment studies for drug discovery.

7. **Lumsden, N.G., Khambata, R.S., Hobbs, A.J. (2012). C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target. Curr Pharm Des, 18(21), 3266-3274.**
While focused on CNP, this review highlighted the broader significance of natriuretic peptide fragments in cardiovascular research.

Experimental Data and Results
Preclinical studies employing ANP (1-11), rat, have yielded important insights into the physiological and pharmacological actions of natriuretic peptides:

- **Blood Pressure Regulation:** Administration of ANP (1-11) in hypertensive rat models induces a dose-dependent reduction in systolic and diastolic blood pressure, mediated by vasodilation and enhanced natriuresis (Kishimoto et al., 1996). The effect is less pronounced than with full-length ANP, suggesting partial agonism or receptor selectivity.

- **Renal Effects:** ANP (1-11) increases glomerular filtration rate and promotes sodium excretion, albeit with a shorter duration of action compared to the parent peptide. These findings support its role in acute modulation of renal function (Kuhn, 2016).

- **Receptor Binding:** Radioligand binding assays demonstrate that ANP (1-11) has lower affinity for NPR-A but can effectively engage NPR-C, implicating this receptor in N-terminal fragment signaling (Koller et al., 1991).

- **Metabolic Stability:** In vivo studies reveal rapid degradation of ANP (1-11) by neutral endopeptidases, limiting its bioavailability but providing a model for studying peptide metabolism and the development of more stable analogs (Vollmar, 1997).

- **Immunomodulation:** Experimental data suggest that ANP (1-11) can attenuate inflammatory cytokine production in models of acute inflammation, indicating potential anti-inflammatory properties (Vollmar, 1997).

Usage Guidelines and Best Practices
ANP (1-11), rat, is supplied as a synthetic peptide, typically in lyophilized form. For experimental use, the following guidelines are recommended:

Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 28 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11578956